Teva to Present at the NASDAQ OMX 25th Investor Program

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the NASDAQ OMX 25th Investor Program in London with Eyal Desheh, Chief Financial Officer, presenting on Tuesday, December 7, 2010.

What: Teva Presentation at the NASDAQ OMX 25th Investor Program, London

Who: Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries

When: Tuesday, December 7, 2010 at 9:00 AM (local time) / 4:00 AM ET

Where: www.tevapharm.com/financial/ or http://investor.shareholder.com/nasdaq/london_Dec2010/eventdetail.cfm?eventid=88975

How: Live over the Internet -- log on to the Web at the address above and register for the event (approx. 10 minutes before). An archive of the webcast will be available on Teva's website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,250 molecules and a direct presence in approximately 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva's leading innovative product, Copaxone®, is the number one prescribed treatment for multiple sclerosis. Teva employs more than 40,000 people around the world and reached $13.9 billion in net sales in 2009.



CONTACT:

IR:
Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin C. Mannix, 215-591-8912
or
PR:
Teva Pharmaceutical Industries Ltd.
Yossi Koren, 972 (3) 926-7687
or
Teva North America
Denise Bradley, 215-591-8974

KEYWORDS:   Middle East  Israel

INDUSTRY KEYWORDS:   Health  Pharmaceutical  General Health

MEDIA:

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.